Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer

Abstract

Objectives: The aims of this study were to investigate the long‐term clinical outcomes of patients with successful versus unsuccessful revascularization with drug‐eluting stents (DES) for chronic total occlusion (CTO). Background: The benefits of successful revascularization of CTO remain unclear. Methods: Consecutive patients (n = 333) with “true” CTO, defined as Thrombolysis In Myocardial Infarction (TIMI) flow grade 0 on angiography and duration ≥3 months, were divided into two groups, those with successful (CTO success group, n = 251) and unsuccessful (CTO failure group, n = 82) revascularization with DES for CTO lesions. The primary endpoint was defined as major adverse cardiac events (MACE) the composite of death, Q‐wave myocardial infarction (MI), or target vessel revascularization (TVR). Results: The CTO success group was significantly younger, with a higher involvement of LAD, and lower incidences of renal failure, previous myocardial infarction, and previous coronary intervention than the CTO failure group. After a median follow up of 1,317 days (interquartile range, 1,059–1,590 days), there were no significant between‐group differences in rate of MACE, both after crude analysis (9.4% vs. 11.8%, log‐rank P = 0.16) and after adjustment (HR 1.17; 95% CI 0.47–2.88, P = 0.53). On multivariate analysis, major predictors of MACE were left ventricle ejection fraction (LVEF) <40% (HR 3.14; 95% CI 1.39–7.09, P = 0.005) and multiple CTO (HR 2.38; 95% CI 1.01–5.71, P = 0.049). Conclusions: Long‐term clinical outcomes were similar in the CTO success and failure groups. Multiple CTOs and LVEF <40% in CTO patients were independent predictors of MACE. © 2011 Wiley‐Liss, Inc.

The results of first line systemic therapy of NSCLC in clinical practice

“…A limitation of this comparison is the relatively low number of patients receiving various treatment regimens based on carboplatin (n = 33). Thirdly, the analysis showed the significant influence of the performance status and the age of patients on their overall survival, which was also observed in the clinical studies addressed for the patients in older age groups [22,23]. Our study also has a few potential drawbacks.…”

Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine

“…[22][23][24] Many studies have already investigated different GD regimens, where the two drugs were used at different doses and schedules, as weekly, biweekly and tri-weekly treatments. 8,9,25,26 The clinical results of those studies were similar in term of clinical response and antitumor efficacy. In a randomized clinical trial there were no survival differences detected with D/G versus weekly D in the 223 patients with good performance status (7.2 months vs. 8.0 months, respectively) or in the 122 poor performance status patients (3.8 months vs. 2.9 months, respectively).…”

“…TTP were 3.5 and 2.3 months for the DG and D regimen, respectively (p = 0.054). 25,26 with aldesleukine ability of activating in vivo different cytokines networks which include IL-5, TNFα, IFNγ.…”

Rola systemowych metod leczenia u chorych na niedrobnokomórkowego raka płuca i złośliwego międzybłoniaka opłucnej: Uaktualnione zalecenia ekspertów

“…W tej grupie wiekowej dobry paliatywny efekt można także uzyskać pod wpływem jednolekowej chemoterapii [99]. Leczenie chorych w 2. stopniu sprawności według skali WHO jest przedmiotem kontrowersji, aczkolwiek niektóre badania wskazują na możliwość uzyskania w tej grupie korzyści pod wpływem jedno-lub dwulekowej chemioterapii [100][101][102].…”